Abstract:Objective To evaluate the expression of epidermal growth factor receptor ( EGFR ) mutation specific antibodies in invasive lung adenocarcinomas, and their sensitivity, specificity, as well as relationship to histological subtypes.Methods Immunostaining with EGFR mutation-specific antibodies, del E746-A750 in exon 19 and L858R in exon 21, was performed in tissue microarrays of 884 cases of resection specimens to study the relationship between the immunophenotypes and morphologic subtypes.The sensitivity and specificity of the stains were compared with gene mutations detected by amplified refractory mutation system-polymerase chain reaction ( ARMS-PCR).Results Of the 884 cases, the expression of del E746-A750 in exon 19 was 3+, 2+, 1+and 0 in 7 cases ( 0.79%) , 38 cases ( 4.30%) , 129 cases (14.59%) and 710 cases (80.32%), respectively.For L858R in exon 21, 3+, 2+, 1+and 0 staining were seen in 82 cases (9.28%), 93 cases (10.52%), 82 cases (9.28%) and 627 cases (70.93%), respectively.For both antibodies, positive expression (1+or more) was mainly observed in lepidic, acinar and papillary predominant subtypes, and rarely seen in solid subtype or invasive mucinous adenocarcinoma ( P=0.014 and 0.016).If 1+to 3+expression was set as positive, the specificity of exon 19/exon 21 reached 98.59%/92.98%, while the sensitivity was relatively lower ( 62.86%/88.89%).If 2+to 3+expression was read as positive, the specificity and sensitivity were 99.30%/97.37% and 25.71%/74.60%for exon 19/exon 21.If only 3+expression was considered positive, the specificity was 100.0%for both antibodies, with a low sensitivity (8.57%for exon 19 and 34.92%for exon 21).Of the 18 cases with E746-A750 del in exon 19 based on molecular detection, the sensitivity of immunohistochemistry for exon 19 was 88.89%if a positive cutoff value≥1+was used;in contrast, of the 8 cases harboring other deletions in exon 19, only two cases were positive as 1+.Conclusions Both the EGFR mutation specific antibodies del E746-A750 in exon 19 and L858R in exon 21 demonstrate high specificity and relatively low sensitivity, and are mostly expressed in lepidic, acinar and papillary predominant subtypes, but rarely in solid subtype or invasive mucinous adenocarcinoma.For cases with 3+expression, a mutational statue for EGFR is likely.For the 2 +positive cases, the accuracy to predict mutation almost reaches 90%, but molecular detection for confirmation is desirable.For the 1 +and negative cases, DNA-based test is essential to avoid false negativity.

Expression and Clinical Significance of A Disintegrin and Metalloprotease 8 (ADAM8) and Epidermal Growth Factor Receptor (EGFR) in Non-small Cell Lung Cancer

P3-015: Clinicopathologic Features and Epidermal Growth Factor Receptor Mutations Associated with Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer

Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

Study on expression and significance of epidermal growth factor receptor in 70 cases with non-small cell lung cancer

Association of CD8 T cell apoptosis and <i>EGFR</i> mutation in non-small lung cancer patients

Expressions of a Disintegrin and Metalloprotease 17 and Epidermal Growth Factor Recepter in Esophageal Squamous Cell Carcinoma and Their Significances

Expression and Clinical Significance of Vascular Endothelial Growth Factor and Epidermal Growth Factor in Non-Small Cell Lung Cancer

Extracellular matrix expression in non small cell lung cancer and its relationship with neo-adjuvant chemotherapy

Expression of ADAM8 in Gastric Carcinoma and Its Association with Clinicopathologic Features

Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.

Expression of Adam28 As a Prognostic Biomarker of Survival in Patients with Early-Stage Non-Small Cell Lung Cancer.

Protein abundance of epidermal growth factor receptor between primary and corresponding metastatic lymph nodes in non-small cell lung cancer

Expression and significance of osteopontin and disintegrin and metalloprotease 8 in patients with lung cancer

Expression of EGFR and RAS/MAPK signal pathway-related proteins and their significance in lung adenocarcinoma

Expressions of Epidermal Growth Factor Receptor (EGFR) and Ki67 in Non-Small Cell Lung Cancer and Correlative Research

Upregulation of a Disintegrin and Metalloprotease 8 is Associated with Progression and Prognosis of Patients with Gastric Cancer

Expressions of cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer

Expression of epidermal growth factor receptor mutation specific antibodies in lung adenocarcinoma:evaluation of sensitivity, specificity and relationship to histologic subtypes

WITHDRAWN: A disintegrin and metalloprotease 8 (ADAM8) expression correlates with prognosis in solid tumors: A systematic review and meta-analysis

[Expression of PD-1/PD-L1 in Lung Adenocarcinoma and Correlation with Epidermal Growth Factor Receptor Mutation Status].